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The dominant cause of premature death in patients suffering from cystic ﬁbrosis (CF) is chronic lung
infection with Pseudomonas aeruginosa. The chronic lung infection often lasts for decades with just one
clone. However, as a result of inﬂammation, antibiotic treatment and different niches in the lungs, the
clone undergoes signiﬁcant genetic changes, resulting in diversifying geno- and phenotypes. Such an
adaptation may generate different host responses. To experimentally reﬂect the year-long chronic lung
infection in CF, groups of BALB/c mice were infected with clonal isolates from different periods (1980,
1988, 1997, 1999 and 2003) of the chronic lung infection of one CF patient using the seaweed alginate
embedment model. The results showed that the non-mucoid clones reduced their virulence over time,
resulting in faster clearing of the bacteria from the lungs, improved pathology and reduced pulmonary
production of macrophage inﬂammatory protein-2 (MIP-2) and granulocyte colony-stimulating factor
(G-CSF). In contrast, the mucoid clones were more virulent and virulence increased with time, resulting
in impaired pulmonary clearing of the latest clone, severe inﬂammation and increased pulmonary
MIP-2 and G-CSF production. In conclusion, adaptation of P. aeruginosa in CF is reﬂected by changed
ability to establish lung infection and results in distinct host responses to mucoid and non-mucoid
phenotypes.
Key words: Pseudomonas aeruginosa; cystic ﬁbrosis; adaptation; chronic lung infection; host response.
Claus Moser, Department for Clinical Microbiology, Copenhagen University Hospital, Rigshospita-
let, Juliane Mariesvej 22, Copenhagen DK-2100, Denmark. e-mail: moser@dadlnet.dk
The majority of adult patients with the inherited
disease cystic ﬁbrosis (CF) have acquired chronic
Pseudomonas aeruginosa lung infection, due to
decreased airway ﬂuid, resulting in reduced
ciliary clearance of aspirated microbes (1). The
induced host response is characterized by an in-
ﬂux of numerous polymorphonuclear neutrophil
granulocytes (PMNs) and an induction of a Th2-
dominated response with pronounced antibody
and IL-4 production (2–4). However, the chronic
P. aeruginosa lung infection resists the host res-
ponse, as well as antibiotic treatment to eradicate
the microorganisms from the lungs (5, 6). The
persistence of the infection is ascribed to the
ability of P. aeruginosa to form bioﬁlms, where
bacteria grow in microcolonies in a self-produced
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95extracellular polymeric matrix, to mutate to mu-
coid phenotypes hyperproducing an exopoly-
saccharide called alginate and to develop resistance
to antibiotics by becoming mutators (6–8). The in-
ﬂammation induced by the chronic P. aeruginosa
lung infection leads to a gradual degradation of the
lung tissue due to PMN proteases and reactive
oxygen species from the PMNs (6, 9, 10).
Although the dominant outcome of the lung
infection in CF is tissue damage and premature
death or lung transplantation, there is a signi-
ﬁcant effect of the inﬂammation on P. aerugino-
sa residing in the lungs (6). The result is a year-
long interplay between the host and the patho-
gen unless the infecting strain is replaced by a
more ﬁt strain, which occasionally is the case
(11). Although replacement of a dominant strain
can take place, it is believed that CF patients are
infected with one clone for several years – often
decades (6, 11). However, even though the
patients are infected with one clone, several dif-
ferent phenotypes are present due to adaptation
(6). The general background and consequences
of adaptation and diversity have received con-
siderable attention from environmental micro-
biologists (12, 13). Early in the course of disease,
intermittent colonization with one ﬁt, often
environmental and physiologically adaptable
clone takes place. In later stages of infection,
genomic adaptation can dominate, e.g. in the
case of hypermutators (14–17).
In the case of P. aeruginosa and CF, adapta-
tion has been demonstrated to be involved al-
readyfrom the initial phasesduring theinterplay
between pathogen and epithelia (18), and con-
tinue during infection (19, 20). This is reﬂected
in approximately 10% larger genome of clinical
P. aeruginosa strains as compared with environ-
mental strains and the PAO1 type strain (21).
Another example of the adaptation of P. aeru-
ginosa during the 20–30 years of chronic lung
infection in CF was demonstrated by Lee et al.
(22), who investigated the ability of in vitro bio-
ﬁlm formation of pulsed-ﬁeld gel electrophoresis
(PFGE) identical non-mucoid clinical strains
from CF patients. Bioﬁlm formation signiﬁ-
cantly changed over time, and the ﬁnding was
that the ability of bioﬁlm formation decreased
from the early isolates to the late isolates (22). In
addition, changes in the quorum-sensing (QS)
status and the production of exoproteases were
observed, and the appearance of hypermutable
strains seemed to increase with the duration of
the lung infection (22). The diversity with dif-
ferent phenotypes and genotypes following the
initial phases probably reﬂects the adaptation to
different niches of the lungs and the subsequent
higher orders of complexity result in increased
ﬁtness of the strain that infected the CF patient
(6, 16, 17). Indeed, the induced inﬂammation
and subsequent tissue destruction may generate
more spatially heterogeneous niches with differ-
ent physiologies (e.g. changed levels of oxygen)
for adapting mutators or recombinants (17, 23).
Animal models mimicking the adaptation dur-
ing chronic P. aeruginosa lung infection are pivotal
tofurtherimprove ourunderstanding ofthe patho-
physiological mechanisms during the persistent in-
fection in CF and related diseases like diffuse pan-
bronchiolitis. However, no known animal model
reﬂects the 20–30 years of bacterial–host interplay
observed in CF. No model reﬂects the fact that
clones of P. aeruginosa isolated at the early stages
of the chronic infection behave signiﬁcantly differ-
ent from the same clones isolated at later or term-
inal stages of the chronic lung infection thousands
of bacterial generations later. Such evolution of the
bacterial clones may induce completely different
host responses, which again may indicate the need
for different treatment strategies.
Based on those observations, we aimed at es-
tablishing a new experimental strategy infecting
different groups of BALB/c mice with PFGE-
identical mucoid and non-mucoid isolatesfromthe
same CF patient isolated during different periods
of her chronic lung infection for 23 years. The ex-
periments were evaluated by quantitative bacter-
iology, macroscopic and microscopic pathology,
as well as pulmonary cytokine production.
MATERIAL AND METHODS
Mice
Female BALB/c mice, 11 weeks of age, were purchased
from M&B Laboratory Animals (Ry, Denmark), and
given unlimited access to chow and water. Mice were left
to acclimatize for 1 week before the experiments were
performed, and all the experiments were performed un-
der the guidelines of the National Ministry of Justice.
CF patient
The set of clonal P. aeruginosa strains, on which the
present animal model is based, was from a female CF
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DF508/3128 del4. She has been chronically infected
with P. aeruginosa since 1971, and had a high number
of precipitating anti-pseudomonas antibodies. How-
ever, the isotypic clones included in the present study
were cultured in 1980 for the ﬁrst time. In 2000, the
patient underwent a double-lung transplant, but was
again chronically infected within a few months with
the same isotypic clone. The PFGE patterns are
shown in Fig. 1.
Bacterial strains
All CF patients at the Copenhagen CF centre are seen
on a monthly basis, and provide a sputum sample for
microscopy and culture. Strains from all patients are
frozen at  801C on a regular basis. The non-mucoid
clonal isolates used in the present study were used in a
recentlypublished study(22), andwereisolated in1980
and 1988 (early isolates), and 1997, 1999 and 2003 (late
isolates). The mucoid clonal isolates are from the same
sputum samples as the non-mucoid clonal isolates
from 1988, 1997 and 2003. To maintain consistency in
our ﬁndings with the clone collection, three non-mu-
coid PFGE identical isolates from two CF patients, as
well as two pairs of early and late isotyped mucoid
isolates from two other chronically infected CF pa-
tientswereincluded inthe study. Infectionofmicewith
these control isolates from different time periods were
evaluated by quantitative bacteriology and macro-
scopic pathology, and mortality was registered.
PFGE analysis was performed as described pre-
viously (24). Evaluation of similarity was performed
as described by Tenover et al. (25).
Colonies of the late non-mucoid (Fig. 3E) and mu-
coid isolates from 2003 are shown for comparison.
QS
Production of acyl-homoserine lactones (AHL) was
detected in the supernatant from overnight bacterial
cultures using the AHL-speciﬁc reporter strains as
described by Hentzer et al. (26).
Challenge procedure
Immobilization of bacteria was performed as de-
scribed previously (27). Brieﬂy, one colony was added
to 100ml sterile ﬁltered oxbroth, and cultured at 371C
for 18h on a gyratory shaker. The overnight culture
was centrifuged at 41C and 4400g. The supernatant
was discarded and the pellet was resuspended in 5ml
sterile serum bouillon [Statens Seruminstitut (SSI),
Copenhagen, Denmark]. One millilitre of the bacter-
ial suspension was mixed with 9ml sterile seaweed
alginate suspension (11mg/ml of 60% guluronic
acid protanal 10/60 (Protan, Drammen, Norway)
dissolved in 0.9% NaCl). The suspension was placed
in a cylindrical reservoir and forced through an 18G
cannula, with a coaxial jet of air blowing on the algi-
nate droplets. The alginate droplets were collected in
a solution of 0.1M CaCl2 Tris-HCl buffer (0.1M, pH
7.0). After 1h of stirring, the alginate beads were wa-
shed twice in 0.9% NaCl. The colony-forming units
(CFU) were controlled by serial dilution and cultured
on a modiﬁed Conradi-Drigalski medium (SSI) selec-
tive for Gram-negative bacteria. Based on dose–
response experiments, the suspension was adjusted
to 10
8CFU/ml for the non-mucoid isolates and
conﬁrmed by colony counts (corresponding to a
challenge dose of 4 10
6CFU per mouse). At this
challenge dose, the early isolates from 1980 or 1988
revealed a signiﬁcantly higher, but acceptable mor-
tality rate at 20–25% as compared with the late iso-
lates (po0.025). In the study comparing the outcome
after infection with mucoid or non-mucoid isolates,
no signiﬁcant differences were observed between the
early mucoid isolate and the three non-mucoid iso-
lates (data not shown). However, survival was sig-
niﬁcantly reduced when mice were infected with either
of the late mucoid isolates from 1997 or 2003, because
only two mice survived in the 2003 group (po0.005).
Therefore, the challenge dose for the mucoid isolates
was reduced to 0.8 10
6CFU per mouse.
At the time of the challenge, mice were anaes-
thetized subcutaneously with a 1:1 mixture of etomi-
date (Jannsen, Birkeroed, Denmark) and midazolam
(Roche, Basel, Switzerland) (10ml/kg body weight),
and tracheotomized (28). An intratracheal challenge
with 0.04ml of P. aeruginosa embedded in seaweed
Non-mucoid Mucoid and non-mucoid pairs
       1988   1997  2003
Fig. 1. Pulsed-ﬁeld gel electrophoresis (PFGE) typing
of the Pseudomonas aeruginosa clones. PFGEtypingof
the P.aeruginosaclonesfromonecysticﬁbrosispatient
chronically infected for 23 years. All non-mucoid
clones (I, II, IV and V) [to the left from the middle
molecular weight latter (MW), III to the right] and the
mucoid (marked clone 2, 4 or 6), non-mucoid pairs (to
the right from the middle MW latter) had the same
pulsed-ﬁeld gel electrophoresis patterns.
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needle. The inoculum was installed in the left lung
11mm from the penetration site (28).
Pentobarbital (DAK, Copenhagen, Denmark)
2.0ml/kg body weight was used to sacriﬁce the ani-
mals (28). Mice were sacriﬁced at day 5, because both
the innate and the adaptive immune responses are
activated at this time point (own observation).
Macroscopic pathology
Upon sacriﬁce, macroscopic signs of pathology were
noted. A broad estimate of the expansion of the af-
fected areas was registered as a fraction of the referred
lung lobe. All estimates were performed blinded.
Histopathology
The lungs were prepared for histopathological ex-
amination as described previously (28). Brieﬂy, the af-
fected lung was ﬁxed in a 4%w/v formaldehyde
solution (Bie & Berntsen, Copenhagen, Denmark)
embedded in parafﬁn wax and cut into 5-mm-thick
sections, followed by haematoxylin and eosin staining.
The entire lung slide was scanned at a low magnitude,
and from an average evaluation of a minimum of ﬁve
representative areas at higher magnitude ( 500) the
type of lung inﬂammation was estimated. The in-
ﬂammatory responses were scored as acute (490%
PMNs), chronic [490% mononuclear cells (MN)],
both types present, neither dominating (PMN/MN) or
noinﬂammation(NI)(28).Thedegreeofinﬂammation
was scored on a scale from 0 to 31, where 0 means NI,
1 means mildfocal inﬂammation, 11mean moderate
to severe focal inﬂammation and 111 means severe
inﬂammation to necrosis, or severe inﬂammation
throughout the lung. In addition, the presence of at-
electasis or micro-abscesses was noted. The histo-
pathological evaluation was performed blinded.
Peptide nucleic acid (PNA)-ﬂuorescence in situ
hybridization (FISH)
To conﬁrm the nature of bacteria-like structures in
the alveoles, deparafﬁnized tissue sections were ana-
lysed by FISH using PNA probes. A mixture of a
Texas Red-labelled, P. aeruginosa-speciﬁc PNA probe
and a ﬂuorescein isothiocyanate (FITC)-labelled,
universal bacterium PNA probe in a hybridization
solution (AdvanDx Inc., Woburn, MA, USA) was
added to each section and hybridized in a PNA-FISH
Workstation at 551C for 90min covered by a lid. The
slides were washed for 30min at 551C in Wash Solu-
tion (AdvanDx Inc.). Vectashield mounting media
with 40,6-diamidino-2-phenylindole (DAPI) (Vector
laboratories, Burlingame, CA, USA) was applied,
and a cover slip was added to each slide. Slides were
read using a ﬂuorescence microscope equipped with
an FITC, a Texas Red and a DAPI ﬁlter.
Quantitative bacteriology
Lungs for quantitative bacteriology were prepared as
described previously (28). In brief, the lungs were re-
moved aseptically and homogenized in 5ml of PBS
and serial dilutions of the homogenate were plated,
incubated for 24h and the numbers of CFU were de-
termined and presented as log CFU per lung.
Cytokine production
The lung homogenates were centrifuged at 4400g for
10min and the supernatants were isolated and kept at
–701C until cytokine analysis. The concentrations in
the lung homogenates of the PMN mobilizer granu-
locyte colony-stimulating factor (G-CSF) and the
PMN chemoattractant and murine IL-8 analogue
macrophage inﬂammatory protein-2 (MIP-2) were
measured by ELISA (R&D, Minneapolis, MN, USA)
according to the manufacturer’s instructions.
Statistical analysis
The number of mice in each group was calculated to
provide apower of0.80 or higher for continuous data.
Statistical calculations were performed using Statview
(Abacus Concepts, Berkeley, CA, USA). The w
2 test
was used when comparing qualitative variables, and
the ANOVA/unpaired t-test was used when compar-
ing quantitative variables. p   0.05 was considered
statistically signiﬁcant.
Table 1. Production of acyl-homoserine lactones in
three PFGE-identical pairs of mucoid and non-mu-
coid Pseudomonas aeruginosa
Clonal isolates C4 C12
Non-mucoid 1988 1 111
Mucoid 1988 11
Non-mucoid 1997   
Mucoid 1997 11
Non-mucoid 2003   
Mucoid 2003   1
Production of acyl-homoserine lactones (AHLs) by the
mucoid clones (2, 4 and 6) and the non-mucoid clones
(1, 3 and 5). Detected in supernatants from overnight
bacterial cultures using AHL-speciﬁc reporter strains.
Presented semiquantitatively from   (no detected pro-
duction) to 111 (high production). Both the early
mucoid and non-mucoid isolates from 1988 produced
both quorum sensing signal molecules, whereas only the
mucoid intermediate clone from 1997 produced both
signal molecules. In contras tt h el a t em u c o i di s o l a t e
from 2003 only produced the C12 signal molecule. Ex-
cept for the early non-mucoid isolate, the non-mucoid
clones did not producequorum sensing signal molecules.
PFGE, pulsed-ﬁeld gel electrophoresis.
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QS
Ascan be seen fromTable 1, the early non-mucoid
strain from 1988 produced both AHL, C4 and
C12. The same was observed from the early and
the intermediate mucoid strains. The late mucoid
strain from 2003 produced only the C12 AHL.
The two late non-mucoid isolates were defec-
tive in producing both AHL.
Quantitative bacteriology
Non-mucoid isolates
Signiﬁcantly higher CFUs were obtained from
the groups of mice infected with any of the two
early isolates as compared with the three groups
infected with one of the late isolates (po0.035;
Fig. 2A).
Mucoid isolates
All mice infected with the late 2003 mucoid iso-
late had bacteria cultured from the lungs at day
5. In contrast, no bacteria were cultured from
any mice infected with the early (1988) or
the intermediate (1997) mucoid isolate. The dif-
ference was statistically signiﬁcant (po0.0001;
Fig. 2C).
Macroscopic pathology
Non-mucoid isolates
In infection with the non-mucoid isolates, only
atelectasis was seen as a pathologic change.
Dissemination of pathology was signiﬁcantly
0
1
2
3
4
5
6
7
8
9
10
Clone6/2003 (n=9)
Clone4/1997 (n=8)
Clone2/1988 (n=10)
0
10
20
30
40
50
60
70
Clone6/2003 (n=18)
Clone4/1997 (n=17)
Clone2/1988 (n=19)
L
o
g
 
C
F
U
/
l
u
n
g
F
r
a
c
t
i
o
n
 
p
a
t
h
o
l
o
g
y
P<0.0001
P<0.0001 P<0.0004
P<0.0007
D C
0
1
2
3
4
5
6
7
8
9
V/2003 (n=9)
IV/1999 (n=11)
III/1997 (n=9)
II/1988 (n=6)
I/1980 (n=7)
0
20
40
60
80
100
V/2003 (n=17)
IV/1999 (n=22)
III/1997 (n=19)
II/1988 (n=13)
I/1980 (n=14)
L
o
g
 
C
F
U
/
l
u
n
g
F
r
a
c
t
i
o
n
 
p
a
t
h
o
l
o
g
y
B A
n.s n.s
n.s
n.s
n.s
n.s
n.s
P<0.035
P<0.035
P<0.0001
P<0.0001
P<0.0015
P<0.0015
Fig. 2. Quantitative bacteriology. Quantitative bacteriology of homogenized lungs from mice infected
with non-mucoid [4 10
6 colony-forming units (CFU) per mouse, panel A] or mucoid (0.8 10
6CFU per
mouse, panel C) pulsed-ﬁeld gel electrophoresis (PFGE)-identical Pseudomonas aeruginosa using the seaweed
alginate embedment model. Evaluated day 5 after infection. A signiﬁcantly faster clearance of the later
non-mucoid clones was seen as compared with the early non-mucoid clones (po0.035). In contrast, both
the early and the intermediate mucoid isolates eradicated, whereas the late mucoid isolate was cultured from
all mice, and even increased in number in four mice (po0.0001). Macroscopic pathology. Macroscopic pathol-
ogy was estimated as a relative affected area of the total lung area. Evaluated at day 5 after infection with
non-mucoid [4 10
6 colony-forming units (CFU) per mouse, panel B] or mucoid (0.8 10
6CFU per mouse,
panel D) PFGE-identical P. aeruginosa using the seaweed alginate embedment model. The dissemination
of macroscopic pathology decreased in mice infected with the later non-mucoid isolates (po0.0015, panel B).
In contrast, signs of macroscopic pathology were almost exclusively present in mice infected with the late
mucoid isolate (po0.0004, panel D). In addition, the observed changes in the lungs from mice infected with
the late mucoid isolate were severe including macro-abscesses, adherences, haemorrhages and areas resembling
air trapping.
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the early isolates as compared with any of the
three groups infected with one of the late isolates
(po0.0015; Fig. 2B). In addition, signs of pa-
thology were signiﬁcantly increased in the group
infected with the latest (2003) isolate as com-
pared with the groups infected with one of other
two late (1997 and 1999) isolates (po0.0001).
Mucoid isolates
Almost exclusively mice infected with the late
mucoid isolate showed signs of macroscopic pa-
thology. The dissemination of the affected areas
was signiﬁcantly increased as compared with the
early (1988) isolate or the intermediate (1997)
isolate (po0.0004 and po0.0007, respectively;
Fig. 2D). In addition, the ﬁndings were severe
with haemorrhages, abscesses, adherences and
areas of air trapping in some of the mice (Fig.
3D). Mouse lung without any sign of inﬂamma-
tion can be seen in Fig. 3C for comparison.
Histopathology
Non-mucoid isolates
In signiﬁcantly more mice infected with one of
the early 1980 or 1988 isolates, a PMN-involved
inﬂammation was observed as compared with
B A
D C
E F
G
Fig. 3. Pathology and clonal phenotypes. Microscopic pictures haematoxylin and eosin (HE staining, Panel A
 600 and B  1000) of lungs of mice infected with the late mucoid Pseudomonas aeruginosa from 2003. Macro-
scopically affected lung parts were isolated and ﬁxed in formaldehyde. Embedded in wax and 5-mm-thick sections
cut for HE staining. In panel A, alveoli next to the pleural cavity can be seen completely ﬁlled up with bacteria.
Polymorphonuclear neutrophil granulocytes (PMNs) can be seen penetrating into the airway lumen. In Panel B
(HE,  1000), alveoli are ﬁlled up with swollen cells, with small nuclei, which may represent macrophages having
phagocytized dead PMNs and therefore contain high amounts of lipids. Macroscopic pictures of lungs infected
with mucoid P. aeruginosa 0.8 10
6 colony-forming units per mouse (early isolate from 1988 panel C and late
isolate from 2003 panel D) using the seaweed alginate embedment model. Mice were sacriﬁced 5 days after in-
fection. In panel D, the lungs are dominated by macro-abscesses and haemorrhagic areas, with minor areas of
normal lung tissue in between. To the left is a lung, that has cleared an infection with a low dose of an early
mucoid P. aeruginosa isolate. No affected areas are seen. For comparison of alginate production, panels E and F
show photos of a non-mucoid and a mucoid P. aeruginosa pair included in the study. In panel G, ﬂuorescence
microscopy pictures ( 600) of peripheral mouse airways stained with P. aeruginosa-speciﬁc Peptide nucleic acid
(PNA)-ﬂuorescence in situ hybridization (FISH) (red) and 40,6-diamidino-2-phenylindole (blue) can be seen. The
lungs have been infected with the late mucoid 2003 isolate. Only areas with bacteria-like structures stained red,
and alveoli are seen ﬁlled up with P. aeruginosa.
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(po0.05; Table 2). This difference did not reach
the level of signiﬁcance as compared with the
2003 isolate (Table 2). The degree of inﬂamma-
tion was signiﬁcantly worse in the mice infected
with the early 1980 isolate as compared with
mice infected with any of the late (1997, 1999 or
2003) isolates (po0.02; Table 2). Mice infected
with the 1988 isolate had a more severe degree of
inﬂammation as compared with mice infected
with the 1997 or the 1999 isolate (po0.002; Ta-
ble 2). The number of mice with atelectasis was
increased in the groups infected with one of the
early isolates from 1980 or 1988 (po0.05; Table
2), although this did not reach the level of sta-
tistical signiﬁcance when comparing 1988 with
2003 (po0.1).
Mucoid isolates
In contrast to mice infected with the non-mucoid
isolates, the most severe histopathology was ob-
served in mice infected with the late 2003 isolate.
PMN-involved inﬂammation was observed in se-
ven out of nine mice infected with the 2003 isolate
as compared with none out of nine and two out of
nine infected with the 1997 or the 1988 isolate,
respectively (po0.01 and po0.05; Table 2).
Three of the mice infected with the 2003 isolate
even had a PMN-dominated inﬂammation.
Moreover, an increased degree of inﬂammation
was observed in the group of mice infected with
the 2003 isolate as compared with the 1988 and
1997 groups (po0.002andpo0.02; Table2),and
micro-abscesses were only observed in mice in-
fected with the 2003 isolate.
Table 2. Histopathology
Non-mucoid isolates Mucoid isolates
Groups Type Degree Atelectasis Type Degree Micro-abscess
I/1980 7 PMN/MN 411 5 mice
0M N 3 1
0N I 0  
II/1988 7 PMN/MN 211 4 mice 0 PMN 0111 0 mice
0M N 5 1 2 PMN/MN 011
0N I 0   0M N 2 1
7N I 7  
III/1997 2 PMN/MN 011 0 mice 0 PMN 0111 0 mice
0M N 2 1 0 PMN/MN 011
8N I 8   0M N 0 1
9N I 9  
IV/1999 2 PMN/MN 011 1 mouse
0M N 2 1
9N I 9  
V/2003 3 PMN/MN 111 1 mouse 3 PMN 3111 3 mice
1M N 3 1 4 PMN/MN 411
4N I 4   0M N 0 1
2N I 2  
Histopathology in the lung samples from mice 5 days after infection with mucoid (0.8 10
6CFU per mouse) or
non-mucoid (4 10
6CFU per mouse) Pseudomonas aeruginosa. Lung slides stained with HE were analyzed with
respect to type of inﬂammation [acute type PMN (490% PMN), chronic type (490% MN), both types present,
neither dominating PMN/MN or no inﬂammation observed (NI)] and degree of inﬂammation [111 (severe
inﬂammation and/or necrosis), 11 (moderate to severe focal inﬂammation), 1 (mild focal inﬂammation) or 0
(no inﬂammation observed)]. In addition, presence of atelectasis or micro-abscesses was noted. The number of
mice with a certain type and degree of inﬂammation is presented. Likewise, the number of mice with atelectasis or
micro-abscesses is presented. An inﬂammationinvolving PMNs were observed in signiﬁcantly moremice infected
with an early isolate (po0.05). In addition, a higher degree of inﬂammation was observed in mice infected with
an early isolate, although the difference between 1988 and 2003 did not reach the level of signiﬁcance (po0.02
for 1980 andpo0.0002 for 1988).Mice infected with the late mucoid P. aeruginosa isolate from 2003 had
signiﬁcantly more often a PMN involving inﬂammation as well as signiﬁcantly higher degree of inﬂammation
(po0.02).
PMN, polymorphonuclear neutrophil granulocytes; MN, mononuclear cells; NI, no inﬂammation; CFU, col-
ony-forming units; HE, haematoxylin and eosin.
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mucoid isolate, the bioﬁlm-embedded bacteria and
the induced inﬂammation had spread to the per-
iphery of the lungs, namely the alveoli lining the
pleural membrane, in accordance with the ob-
servation that the chronic P. aeruginosa lung in-
fection in CF patients is also a disease of the
smaller airways (Fig. 3A) (29). In addition, PMNs
invading the airway lumen could be seen in (Fig
3A). To support that it was actually P. aeruginosa
that was seen in the peripheral airways of a fraction
of mice infected with the late mucoid 2003 isolate,
staining with PNA-FISH speciﬁc for P. aeruginosa
was performed (Fig. 3G). The bacteria-like struc-
tures were speciﬁcally stained with the PNA-FISH,
conﬁrming the origin of the structures. No such
staining was seen in areas without bacteria-like
structures. Another striking feature was the ob-
servation of large, round inﬂammatory cells or
foamy cells in some of the alveoli from mice in-
fected with the 2003 isolate (Fig. 3B). In those
areas, bacteria-like structures were not identiﬁed.
Comparisons between groups infected with
the mucoid and the non-mucoid isolates were
not carried out because the infection dose was
reduced ﬁve times in mice infected with the mu-
coid isolates. However, it is notable that with
this reduced infection dose, the histopathology
in the group infected with the 2003 mucoid iso-
late was the worse of all groups.
Cytokines
Non-mucoid isolates
Although the highest levels of G-CSF were
measured in mice infected with the early isolates,
this did not reach statistical signiﬁcance (Fig.
4A). The highest levels of MIP-2 were measured
in the lung homogenates from mice infected with
one of the early isolates from 1980 or 1988. The
MIP-2 levels were signiﬁcantly increased in the
lungs of the 1980 group as compared with the
1997, 1999 and 2003 groups (po0.005; Fig. 4A).
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Fig. 4. Pulmonary granulocyte colony-stimulating factor (G-CSF) and macrophage inﬂammatory protein-2
(MIP-2) production. Pulmonary production of G-CSF and MIP-2 in mice at day 5 after infection with non-
mucoid [4 10
6 colony-forming units (CFU) per mouse, panel A) or mucoid (0.8 10
6CFU per mouse, panel B)
Pseudomonas aeruginosa isolates from different periods of chronic lung infection in a cystic ﬁbrosis patient.
Measured in supernatants from homogenized lungs. In mice infected with the non-mucoid isolates, the highest
production of the inﬂammatory markers was observed in the groups infected with the early isolates (po0.005 for
MIP-2; NS for G-CSF). In contrast, only mice infected with late mucoid isolate showed a signiﬁcant pulmonary
G-CSF and MIP-2 response (po0.02 for MIP-2 and G-CSF).
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The G-CSF levels were signiﬁcantly increased in
the lung homogenates from mice infected
with the late 2003 isolate as compared with mice
infected with the 1997 or the 1988 isolate
(po0.04 and po0.02, respectively; Fig. 4B).
Likewise, the levels of MIP-2 in the lung homo-
genates from mice infected with the 2003 isolate
were approximately 10–100-fold higher than in
mice infected with the 1997 or the 1988 isolate
(po0.02 and po0.006, respectively; Fig. 4B).
No signiﬁcant differences in either G-CSF or
MIP-2 levels in the lung homogenates between
mice infected with the 1997 or the 1988 isolates
were observed (Fig. 4B).
DISCUSSION
The present serial animal experiments were un-
dertakenwithearly,intermediate andlateisolates
of P. aeruginosa, with the same genotype based
on identical PFGE patterns, causing chronic lung
infection for decades in one CF patient. The
reason for this approach was that chronic lung
infections in mice cannot be maintained for more
than 2–3 weeks. Using this concept, the study
revealed differences in pathogenicity between the
mucoid and the non-mucoid isolates. In addition,
an evolution of virulence was observed. Non-
mucoid isolates seemed to reduce their virulence,
whereas mucoid isolates increased or at least
maintained their virulence.
Rodents seem to be naturally resistant to
P. aeruginosa lung infections and planktonic
growing bacteria are easily cleared from the
mice, except when mice are given a lethal infec-
tion dose. Therefore, in the majority of animal
models of chronic P. aeruginosa lung infection
embedded bacteria in either agar, agarose, sea-
weed or their own native alginate are used (27,
28, 30). However, even those models have a lim-
ited duration of 2–3 weeks (28, 30). In other
models this problem is overcome by repeated
exposure of bacteria; however, mice either suc-
cumb to or become resistant to this procedure
(31, 32). Adding P. aeruginosa to the drinking
water resulting in aspiration of bacteria to the
lower airways in a fraction of the mice, or in-
stalling a plastic tube colonized with P. aerugi-
nosa in a main bronchus, can signiﬁcantly
increase the duration of the infection in mice (33,
34). However, these alternatives are still limited
to the life span of the mouse at the most extreme,
and only investigate one single isolate, often
being the sequenced laboratory strain PAO1.
None of those models can reﬂect the 20–30 years
of bacterial exposure to host responses and anti-
biotics, which, from a bacterial perspective, may
represent as much as 65000 generations (35).
From a human perspective, this corresponds to
2.5 million years or the times of existence of
Homo erectus that preceded H. sapiens.
Indeed, signiﬁcant adaptations were observed
in the present study. No signiﬁcant difference in
the virulence between the non-mucoid and the
mucoid early isolates was observed. This corre-
sponds with the observations that CF patients
often are colonized recurrently with non-mucoid
strains in the lungs before onset of the chronic
lung infection (6). The shift to the mucoid phe-
notype is caused by mutations in the muc genes
that function as AlgT repressors (36–38). Acti-
vated PMNs have been shown to be able to
cause such mutations (39). Therefore, repeated
infections with non-mucoid isolates inducing in-
ﬂammation to a certain degree may be able to
induce mutations resulting in mucoidy, and the
two early non-mucoid isolates did induce sig-
niﬁcant inﬂammation. A control experiment
with similar sets of phenotypic non-mucoid
sequential P. aeruginosa from two other CF
patients conﬁrmed our ﬁndings of highest viru-
lence in the early isolates (data not shown).
In agreement, non-mucoid phenotypic sets of
P. aeruginosa clones isolated during different
time periods of the chronic lung infections in a
number of CF patients were analysed for their
ability to generate in vitro bioﬁlms, hypermut-
ability, colony morphology, motility, QS status
and production of virulence factors (22). The
early isolates harboured most of these abilities,
and presumably would be the most virulent (25).
In later stages of the chronic lung infection,
the differences in virulence between simulta-
neously isotypic mucoid and non-mucoid iso-
lates became distinct. Whereas the virulence and
the ability to establish a chronic lung infection of
the non-mucoid isolates seemed to decline, the
virulence of the two late mucoid isotypes in-
creased and the infection dose had to be reduced
ﬁve times. Using the reduced infection dose, the
course of the infection became benign in mice
infected with the intermediate 1997 isolate,
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late 2003 isolate could not eliminate the infec-
tion, and severe inﬂammation was induced.
Therefore, although the presented results
indicate that only the mucoid 2003 isolate had
the ability to generate infection and inﬂamma-
tion, the virulence was gradually increasing from
the early mucoid 1988 isolate as demonstrated
by infection with a higher infection dose. Fur-
thermore, similar ﬁndings of increasing viru-
lence were observed for two other clinical sets of
mucoid sequential early and late P. aeruginosa
isolates. The sequentially increasing differences
in the virulence of mucoid and non-mucoid
isolates were best evaluated by the histopathol-
ogy, especially with the observation of the late
mucoid strain generating inﬂammation and in-
fection in the alveoli, whereas the non-mucoid
strains almost exclusively infected more central
airways. This phenomenon is interesting because
the beads embedding mucoid or non-mucoid
isolates are similar in size (median diameter
60mm) (27) and therefore will be arrested in the
larger airways during challenge (40). However,
likewise, in the earlier studies from our group,
only mucoid strains were capable of proceeding
to the smaller airways of the lungs (28, 30).
Furthermore, in the small, peripheral airways
of the lungs, the bacteria generate stronger in-
ﬂammatory responses because they are in con-
tact with both residing alveolar macrophages
and arein closecontact withthecapillaries, from
where the inﬂammatory cells migrate into the
airspace (41). Experimentally, this supports
the theory that mucoid strains primarily reside
in the peripheral, respiratory zones of the lungs,
in contrast to the non-mucoid strains, which
probably mainly reside in the larger, conductive
airways (6).
The groups of mice with the more severe
course of the infection, which were the groups
infected with the early non-mucoid strains or the
late mucoid strains, also showed the highest
production of MIP-2 (a murine IL-8 analogue)
and the important PMN mobilizerG-CSF. These
observations correspond with the observation
in CF patients where IL-8 is considered an im-
portant PMN chemoattractant, and G-CSF cor-
relateswithpoorlungfunctionandinductionofa
Th2-dominated response (42, 43). Whether these
clones also induce a Th2-dominating response in
mice remains to be investigated. Moreover, the
maintained C12 production of the late mucoid
isolate isinline withthe observation that C12 can
function as a chemoattractant, either directly or
through induction of IL-8 (44).
A striking new observation during the histo-
pathologic evaluation was the presence of swol-
len or foamy inﬂammatory cells located inside
the alveoli in a fraction of the mice infected with
the late mucoid 2003 isolate. The cause of the
swollen cells is unknown, but they could be
macrophages with a foamy appearance, indicat-
ing lipid phagocytosis due to necrotic PMNs.
This phenomenon requires further investigation.
QS has previously been reported to be an im-
portant control system of virulence in P. aerugi-
nosa lung infections, but also in extrapulmonary
P. aeruginosa infections (45, 46). However, in
contrast to the early isolates the late and most
virulent mucoid strain from 2003 only produced
the C12 homoserine lactone, suggesting a QS-
independent virulence factor taking over infec-
tion control during the year-long adaptation of
the chronic lung infection. Because alginate
production is independent of QS, this may be the
one decisive factor enabling P. aeruginosa to re-
main in the CF lungs at later stages of the disease
(47). Ina follow-upstudy by Leeandcolleagues, it
was indeed observed that the mucoid strains used
in the present study maintained their ability to es-
tablish classic in vitro bioﬁlms in the ﬂowchamber
system (B. Lee, personal communication). More-
over, previous animal studies have reported mu-
coidy of P. aeruginosa to be a pivotal virulence
factor during lung infections (30, 48, 49).
Whether the distinct and changing virulence
of non-mucoid and mucoid P. aeruginosa iso-
types observed in the present study represents a
general behaviour for chronic P. aeruginosa lung
infections in CF has to be conﬁrmed in future
studies involving more isotypic sets of bacteria.
However, involving two other sets of non-
mucoid and mucoid isotypic P. aeruginosa con-
ﬁrmed our ﬁndings supporting the importance
of involving the time perspective in animal
models of chronic P. aeruginosa lung infections.
Diversiﬁcation and adaptation has also
been reported for diseases and conditions like
Helicobacter pylori infections, characterized
by year-long colonization of the gastric and
duodenal mucosa resulting in ulcers, and with
time, complications like cancer. During these
periods of colonization, the strains undergo
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recombinations, resulting in host adaptations,
but perhaps also altered virulence (50,51). Like-
wise, adaptations have been reported in Porphyr-
omonas gingivalis colonizing the oral cavity for
years, as well as Streptococcus mutans (52,53).
Such intra-strain evolution can probably be de-
monstrated for other chronic colonizers in a
stressful environment with the potential of becom-
ing pathogenic. The present concept may also be
applicable to model systems with those pathogens.
In conclusion, here we present a novel animal
experimental strategy for investigation of year-
long chronic infections and colonizations. Using
this concept, important sequential differences
in host responses were observed. Finally, our
observations suggest a pivotal role for mucoidy
in generating chronic P. aeruginosa lung infec-
tion in the peripheral airways of CF patients.
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